kabutan

FunPep Company Limited(4881) Summary

4881
TSE Growth
FunPep Company Limited
86
JPY
0
(0.00%)
Dec 12, 3:30 pm JST
0.55
USD
Dec 12, 1:30 am EST
Result
PTS
outside of trading hours
85.5
Dec 12, 9:49 pm JST
Summary Chart Historical News Financial Result
PER
PBR
1.65
Yield
ー%
Margin Trading Ratio
Stock Price
Dec 12, 2025
Opening Dec 12, 9:00 am
86 JPY 0.55 USD
Previous Close Dec 11
86 JPY 0.55 USD
High Dec 12, 9:28 am
87 JPY 0.55 USD
Low Dec 12, 9:13 am
85 JPY 0.54 USD
Volume
182,500
Trading Value
0.02B JPY 0.10M USD
VWAP
86.24 JPY 0.55 USD
Minimum Trading Value
8,600 JPY 55 USD
Market Cap
3.49B JPY 0.02B USD
Number of Trades
48
Liquidity & Number of Trades
As of Dec 12, 2025
Liquidity
Mid
1-Year Average
289
1-Year High Dec 23, 2024
11,780
Margin Trading
Date Short Interest Long Margin Positions Ratio
Dec 5, 2025 0 3,240,600
Nov 28, 2025 0 3,179,600
Nov 21, 2025 0 3,264,800
Nov 14, 2025 0 3,418,900
Nov 7, 2025 0 3,614,800
Company Profile
FunPep Company Limited is a spin-off from Osaka University's Institute for Protein Research, focusing on research and development of pharmaceuticals using functional peptides.
Sector
Pharmaceuticals
FunPep Company Limited engages in the research and development of pharmaceuticals and other products using functional peptides. The company's strength lies in its proprietary drug discovery platform technology "STEP UP" for antibody-inducing peptides, enabling the creation of development candidates for various target proteins as alternatives to antibody drugs. Additionally, FunPep is advancing the development of SR-0379, a treatment for skin ulcers. The company aims to generate new development candidates through collaborative research with universities and promotes development through partnerships with pharmaceutical companies. In the future, FunPep aspires to achieve significant profit growth through royalty income from the commercialization of its development products. The company's mission is to contribute to society by developing new pharmaceuticals that help reduce medical costs and patient burden.